Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study
Fig 2
(original figure, no copyright permission required, created with BioRender.com), Abbreviations: A/B, atezolizumab plus bevacizumab; CT, computed tomography; FMT, fecal microbiota transplant; HCC, hepatocellular carcinoma; IT, immunotherapy; mRECIST, modified Response Evaluation Criteria in Solid Tumors; RECISTv1.1, Response Evaluation Criteria in Solid Tumors version 1.1.